INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/05/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/04/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Savara Inc.("Savara" or the "Company") (NASDAQ:SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 06/03/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
- NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 06/02/2025
|
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates
- NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
- 05/30/2025
|
SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money
- NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
- 05/28/2025
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
- NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
- 05/28/2025
|
Levi & Korsinsky Launches Fraud Investigation on Behalf of Savara Inc. (SVRA) Shareholders
- NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Savara Inc. ("Savara Inc.") (NASDAQ:SVRA) concerning possible violations of federal securities laws. On May 27, 2025, the company announced that the FDA issued a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP.
- 05/28/2025
|
Savara Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
- BOSTON, MA / ACCESS Newswire / May 28, 2025 / Block & Leviton is investigating Savara Inc. (Nasdaq:SVRA) for potential securities law violations. Investors who have lost money in their Savara Inc. investment should contact the firm to learn more about how they might recover those losses.
- 05/28/2025
|
INVESTOR ALERT: Investigation of Savara Inc. (SVRA) Announced by Holzer & Holzer, LLC
- ATLANTA, May 27, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) complied with federal securities laws. On May 27, 2025, Savara announced that it had received a refusal to file letter from the FDA for the Biologics License Application of MOLBREEVI as a therapy to treat patients with autoimmune pulmonary alveolar proteinosis. Following this news, the price of the Company's stock dropped.
- 05/27/2025
|
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?
- Savara Inc. SVRA on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy for treating patients with autoimmune Pulmonary Alveolar Proteinosis (PAP).
- 05/27/2025
|
BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
- Block & Leviton is investigating Savara Inc. (Nasdaq: SVRA) for potential securities law violations. Investors who lost money should contact the firm.
- 05/27/2025
|
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manuf.
- 05/27/2025
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On May 21, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 85,000 shares of the Company's common stock and restricted.
- 05/23/2025
|
Savara Announces Participation in Jefferies Global Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the Jefferies Global Healthcare Conference on June 4, 2025, at 9:20am ET/6:20am PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company's corporate website and will be archived for 90 days. Abou.
- 05/22/2025
|
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden and improves health-related quality of life outcomes in patients with aPAP. ATS 2025 Posters Poster Ti.
- 05/18/2025
|
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and provided a business update. “At the end of 1Q 2025, we announced the on-time submission of the MOLBREEVI BLA to the FDA for the treatment of autoimmune PAP and requested priority review,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “If Priority Review.
- 05/13/2025
|
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company's corporate website and will.
- 05/12/2025
|
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will be hosting 1x1 meetings and participating in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025 at 10:30am EST/7:30am PST. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company's corporate webs.
- 05/01/2025
|
Savara: Make-It-Or-Break-It Molbreevi BLA Filing
- Savara, Inc. focuses exclusively on developing its sole therapeutic product, MOLBREEVI. Its investment thesis highlights the potential of MOLBREEVI to address unmet medical needs in autoimmune pulmonary alveolar proteinosis (aPAP). Rating justification: Strong clinical data, multiple FDA designations and a clear path to regulatory approval make Savara a compelling investment opportunity.
- 04/21/2025
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees. On April 9, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to seven new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 107,000 shares of the Company's common stock and restri.
- 04/11/2025
|
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will be presented at the 65th Congress of the German Society of Pneumology (DGP) in Leipzig, Germany taking place April 9-12 and at the 65th Annual Meeting of the Japanese Respiratory Society (JRS) taking place April 11-1.
- 04/07/2025
|
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update. “Completing submission of the BLA is an important milestone in potentially addressing the significant unmet need of people living with aPAP, a rare and debilitating lung disease,” said Matt Pauls, Chair and Chief Executive.
- 03/27/2025
|
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a tre.
- 03/26/2025
|
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA marks an important milestone for the Company and the aPAP community,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “We believe this unprecedented body of data demonstrates MOLBREEVI improves pulm.
- 03/26/2025
|
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, in San Francisco, CA. The Company will also host an Industry Theater titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)” at the meeting. ATS 2025 Posters Poste.
- 03/17/2025
|
Savara Announces Participation in the Leerink Global Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink Global Healthcare Conference and participate in a fireside chat on Tuesday, March 11th, 10:40am ET/7:40am PT. The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company's corporate website at https://savaraphar.
- 03/03/2025
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On February 12, 2025, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 97,500 shares of the Company's common stock and restr.
- 02/14/2025
|
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, “Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution" was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, r.
- 01/30/2025
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company's common stock and rest.
- 12/23/2024
|
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with.
- 12/18/2024
|
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent r.
- 12/17/2024
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company's common stock and restr.
- 11/22/2024
|
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Presentation Details Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Re.
- 11/22/2024
|
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of The Balancing Act®, sponsored by Savara and featuring autoimmune Pulmonary Alveolar Proteinosis (aPAP), is airing on Lifetime TV's Behind the Mystery™ a recurring series on The Balancing Act® television show devoted to advocating for people with rare and genetic diseases. The episode centers on the diagnostic.
- 10/22/2024
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On October 17, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 95,000 shares of the Company's common stock and restri.
- 10/18/2024
|
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for poster presentation at the CHEST 2024 Annual Meeting, taking place October 6-9 in Boston. The Company is also sponsoring an Industry Symposium at the meeting. Details are as follows: Accepted Abstract Title: “A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aP.
- 10/01/2024
|
Savara Announces New Employment Inducement Grant
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 25, 2024, Savara's Board of Directors granted the inducement awards to Braden Parker, who joined the Company as Chief Commercial Officer on September 24, 2024. The inducement awards consist of options to purchase 170,000 shares of the Company's common stock and restricted stock.
- 09/27/2024
|
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the Savara Early Access Program, a molgramostim Expanded Access Program (EAP) for patients with aPAP. The program enables physicians to request molgramostim for eligible aPAP patients in select geographies where the product is not commercially available and in compliance with local regulatory requirements. The Savara Early Ac.
- 09/27/2024
|
Savara to Host Analyst and Investor Webinar on September 30, 2024
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, will host an analyst and investor webinar on September 30, 2024 from 8:30-9:30 a.m. ET to present data from the Phase 3 IMPALA-2 clinical trial of molgramostim inhalation solution (molgramostim) in autoimmune Pulmonary Alveolar Proteinosis (aPAP) and provide updates on the global commercial landscape and the Company's market development work.
- 09/23/2024
|
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at the European Respiratory Society (ERS) Congress 2024, taking place September 7-11, 2024, in Vienna, Austria. The Company is also sponsoring an Industry Symposium at the Congress. Details are as follows: Accepted Abstract Title: “Inhaled Molgramostim Improves Pulmonary G.
- 08/15/2024
|
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday?
- The latest trial study from Savara Inc SVRA met its primary endpoint.
- 06/26/2024
|
Savara's rare lung disease drug meets main goal in late-stage study
- Savara on Wednesday said its experimental drug, molgradex, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness.
- 06/26/2024
|
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2 clinical trial. IMPALA-2 is a 48-week, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of molgramostim 300 mcg administered once daily by inhalation with matching placebo in adult patients with aPAP (NCT04544293). Molgramostim is an inhal.
- 06/26/2024
|
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in pat.
- 06/25/2024
|
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
- Though risky, there are certainly plenty of penny stocks to buy that have the potential to significantly boost portfolio returns. Of course, patience and a growth-friendly market are required for the kind of major upside most growth investors are looking for over a five year time frame.
- 06/19/2024
|
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
- Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.
- 06/11/2024
|
Savara: The Binary Bet On Phase 3 Data
- Savara is a biotech company focusing on the treatment of autoimmune pulmonary alveolar proteinosis. The company's valuation will be heavily impacted by the results of its upcoming IMPALA-2 trial for its drug Molgramostim. The trial results are expected to be announced by the end of Q2 2024, and we believe several measures are likely to show efficacy.
- 06/07/2024
|
Savara to Present at the Jefferies Global Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clin.
- 05/29/2024
|
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara's partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP. Below are summaries of the posters presented: Poste.
- 05/19/2024
|
Savara Announces New Employment Inducement Grant
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 15,000 shares of the Company's common stock and restricted stock units (RSUs) cover.
- 05/16/2024
|
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. “The IMPALA-2 trial remains on-track and we look forward to reporting top line results by the end of the second quarter,” said Matt Pauls, Chair and CEO, Savara. “Following that, and assuming positive data, we expect to file a BLA in the fi.
- 05/09/2024
|
Savara to Present at the Citizens JMP Life Sciences Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinica.
- 05/07/2024
|
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA. “We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development.
- 04/08/2024
|
Savara Announces New Employment Inducement Grant
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024, Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 125,000 shares of the Company's common stock and restricted stock units (RSUs) covering a.
- 03/22/2024
|
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update. “We look forward to reporting IMPALA-2 top line results at the end of the second quarter and, assuming positive data, anticipate filing the BLA in the first half of 2025,” said Matt Pauls, Chair and CEO, Savara. “2023 was.
- 03/07/2024
|
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Sava.
- 03/06/2024
|
Savara Announces New Employment Inducement Grant
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On January 31, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 70,000 shares of the Company's common stock and restricted stock units (RSUs) c.
- 02/02/2024
|
3 stocks to turn $100 into $1,000 in 2024
- The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
- 02/01/2024
|
Savara to Present at Two Upcoming Healthcare Conferences
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Co.
- 01/31/2024
|
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive diagnosis of aPAP, a rare autoimmune lung disease mediated by autoantibodies targeting GM-CSF. Autoimmune PAP accounts for approximately 90% of all patients with PAP and has an estimated diagnosed prevalence of se.
- 12/21/2023
|
Savara Added to the NASDAQ Biotechnology Index
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to.
- 12/20/2023
|
Savara Announces New Employment Inducement Grant
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On December 11, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 110,000 shares of the Company's common stock and restricted stock units (RSUs).
- 12/15/2023
|
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 at 1:00pm PT/4:00pm ET. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Sav.
- 11/21/2023
|
Savara to Present at the Jefferies London Healthcare Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023 at 12:00pm GMT/7:00am EST. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is.
- 11/08/2023
|
Savara Announces New Employment Inducement Grant
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On October 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 50,000 shares of the Company's common stock and restri.
- 10/06/2023
|
3 Penny Stocks to Provide 1,000% Returns Over the Next Decade
- While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models, high debt, dwindling market share, and uncertain prospects.
- 09/27/2023
|
The 3 Best Penny Stocks to Buy Now: September 2023
- A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that we can take advantage of, with little capital but perhaps with great returns.
- 09/12/2023
|
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clin.
- 09/05/2023
|
Savara Announces New Employment Inducement Grant
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees. On August 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 150,000 shares of the Company's common stock. These equ.
- 08/04/2023
|
Savara: A Speculative Play
- Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second quarter of 2024. An update investment analysis around Savara follows in the paragraphs below.
- 07/16/2023
|
Savara to Present at the Jefferies Healthcare Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical s.
- 06/02/2023
|
Why Shares of Savara Jumped on Tuesday
- Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.
- 05/16/2023
|
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
- 03/06/2023
|
Why Shares of Savara Soared This Week
- The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
- 01/27/2023
|
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on September 12, 2022 on Savara's website at www.savarapharma.com/investors/events-presentations/ and archived for 90 d
- 09/01/2022
|
3 Top Breakout Stocks to Add to Your Portfolio Now
- Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
- 07/08/2022
|
Savara to Present at Jefferies Healthcare Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies Healthcare Conference on June 8, 2022 at 1:00 pm ET in New York City. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceuti
- 06/01/2022
|
After Golden Cross, Savara Inc. (SVRA)'s Technical Outlook is Bright
- When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- 05/23/2022
|
Savara to Present at Oppenheimer's 32nd Annual Healthcare Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer's 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical
- 03/09/2022
|
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara's website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days. About Savara Savara is a
- 01/04/2022
|
Savara to Present at the Jefferies London Healthcare Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021. A pre-recorded, on-demand webcast of Savara's presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the pr
- 11/10/2021
|
Savara to Present at the Inaugural Piper Sandler Lung Day
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a Fireside Chat at the Inaugural Piper Sandler Lung Day on Friday, October 15, 2021 at 10:30 am ET / 7:30 am PT. Following the event, a replay of the webcast will be available through the Investors page of Savara's website at www.savarapharma.com/investors/events-presentations/ and will be archiv
- 10/07/2021
|
Savara to Participate in Two Upcoming Investor Healthcare Conferences
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare conferences: H.C. Wainwright 23rd Annual Global Investment Conference: A pre-recorded webcast of the presentation will be available beginning at 7:00 AM ET / 4:00 AM PT on September 13, 2021. Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: A live webcast of th
- 09/07/2021
|
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On September 2, 2021, the Compensation Committee of Savara's Board of Directors granted inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 200,000 shares of the Company's common stock and restricted
- 09/03/2021
|
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On August 16, 2021, the Compensation Committee of Savara's Board of Directors granted inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 200,000 shares of the Company's common stock and restricted st
- 08/20/2021
|
5 Penny Stocks Insiders Are Buying
- When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
- 08/19/2021
|
Savara Reports Second Quarter 2021 Financial Results and Provides Business Update
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the second quarter ending June 30, 2021 and provided a business update. “Over the last 9 months we streamlined our portfolio, reduced and restructured the organization, and significantly strengthened the balance sheet so that we could focus solely on advancing the pivotal Phase 3 IMPALA 2 clinical trial,” said Matt Paul
- 08/12/2021
|
Savara (SVRA) Initiates Dosing in Pivotal Lung Disorder Study
- Savara (SVRA) is developing its lead pipeline candidate, molgramostim, as a potential treatment for autoimmune pulmonary alveolar proteinosis.
- 07/01/2021
|
Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo. Molgramostim is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial is expected to be conduct
- 06/30/2021
|
Savara: They Failed Once, But They Are Trying Again
- Savara failed a key phase 3 trial in aPAP.
- 06/07/2021
|
Savara to Present at the Jefferies Virtual Healthcare Conference
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at le
- 05/26/2021
|
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 05/22/2021
|
Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's web
- 05/17/2021
|
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Company's Board of Directors granted a newly hired employee the option to purchase 175,000 shares of the Company's common stock and restricted stock units (RSUs) covering 100,000 shares of the Company's common stock. These equity awards were granted pursuant to Rule 5635(c)(4) of the N
- 05/14/2021
|
7 Reddit Penny Stocks to Buy for a Biotech Boom
- So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.
- 04/16/2021
|
7 Penny Stocks with Interesting Catalysts
- While penny stocks are always incredibly risky ventures, these publicly traded companies offer interesting catalysts to consider. The post 7 Penny Stocks with Interesting Catalysts appeared first on InvestorPlace.
- 04/09/2021
|
7 Reddit Penny Stocks to Keep Your Eye on for Big Movement
- Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.
- 03/24/2021
|
7 Reddit Penny Stocks Seeing the Most Chatter Today
- Retail investors over on Reddit Penny Stocks are showing interest in quite a few interesting players today that investors will want to note. The post 7 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on InvestorPlace.
- 03/18/2021
|
SVRA Stock Price Increases Over 10% Pre-Market: Why It Happened
- The stock price of Savara Inc (NASDAQ: SVRA) is trading at above 10% pre-market. This is why it happened.
- 03/17/2021
|
Savara Stock Rallies: Technical Analysis Levels
- Savara Inc. (NASDAQ:SVRA) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target.
- 03/16/2021
|
SVRA Stock Price Increases Over 30% Pre-Market: Why It Happened
- The stock price of Savara Inc (NASDAQ: SVRA) has increased by over 30% pre-market. This is why it happened.
- 03/16/2021
|
Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' Option
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $1.45 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors pre-funded warrants t
- 03/15/2021
|
SVRA Stock Price Increases Over 10% Pre-Market: Why It Happened
- The stock price of Savara Inc (NASDAQ: SVRA) has increased by over 10% pre-market. This is why it happened.
- 03/15/2021
|
Savara Announces Proposed Public Offering of Common Stock
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. In addition, Savara is offering to certain investors the right to purchase pre-funded warrants in lieu of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or a
- 03/10/2021
|
Is the Options Market Predicting a Spike in Savara (SVRA) Stock?
- Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.
- 02/05/2021
|
Savara Provides Pipeline and Business Update
- AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company's pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. “I am grateful for the opportunity to be a part of the Savara team,” said Matt Pauls, Chairman and CEO, Savara. “Over the last few months, we have moved decisively and with urge
- 12/10/2020
|
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
- Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial. Since that time, Savara has met with the FDA and has designed a new Phase 3 trial, IMPALA 2, that capitalizes on the strong points of Molgradex in IMPALA.
- 11/23/2020
|
